Abstract. Dengue fever, caused by four serotypes of a mosquito-borne virus, is a growing problem in tropical countries. Currently, there is no treatment or vaccine. We evaluated safety and immunogenicity of two doses, given six months apart, of seven formulations of dengue tetravalent live-attenuated vaccine (containing different concentrations of the component viruses) versus placebo in 59 flavivirus-seronegative Thai adults. The first dose was the more reactogenic. Most volunteers experienced clinically moderate fever, headache, myalgia, eye pain or rash 7-11 days after injection, generally lasting three days or less. Modest decreases in platelets and neutrophils were observed. After one dose, 58% of dengue recipients seroconverted (neutralizing antibody level Ն 1:10) against Ն 3 serotypes; 35% seroconverted against all four. After the second dose, seroconversion was 76% and 71%, respectively. All subjects seroconverted to serotype 3 after one dose. Serotype 4 elicited the lowest primary response but the highest increase in seroconversion after the second dose.
INTRODUCTION
Dengue infection is caused by dengue virus serotypes 1-4 (DEN 1-4). The principal mosquito vector for dengue, Aedes aegypti, is present in many countries, concentrated in the urban metropolitan areas of the tropics. In the last 20 years dengue fever and a severe form of the disease, dengue hemorrhagic fever (DHF)/dengue shock syndrome (DSS), have emerged as the most important human arthropod-borne viral disease. It is estimated that up to 100 million cases of dengue fever occur annually, worldwide. Approximately 250,000 cases of DHF are officially notified to the World Health Organization (WHO), and the true incidence is undoubtedly several-fold higher. Currently dengue is endemic/epidemic in tropical areas including Asia, Africa, the Americas, and some Pacific Islands. [1] [2] [3] The incidence of DHF is highest in Asia, especially in Thailand and Vietnam where the various forms of DHF and DSS most affect infants and children. In Vietnam between 1986 and 1990, the average annual hospitalization rate for children up to 14 years with DHF or DSS was as high as 448.9 per 100,000 children. In addition, dengue infection has been reported to be a major cause of febrile illness among U.S. troops during deployments in dengue-endemic areas. 4 Case-fatality of DHF in Asian countries and in the Americas is 4-8%. At present mosquito control is the only weapon against dengue fever, and even this is hampered by a lack of effective vector control programs, as evidenced by the frequent outbreaks of DHF in several countries. 3 Over the past 20 years several live-attenuated dengue candidate vaccines have been evaluated in humans, most of which were found to be poor vaccines due to either underattenuation (i.e., the vaccines made the volunteers too ill) or over-attenuation (i.e., the vaccines did not induce an immune response). 5 The Mahidol University group from Thailand successfully developed candidate live-attenuated vaccines for dengue serotype 1, 2, and 4 viruses in primary dog kidney cells and for serotype 3 in primary green monkey kidney cells. These vaccines have been tested as monovalent, bivalent, trivalent, and tetravalent vaccines in several dozen volunteers, and were found to be safe and immunogenic in both Thai adults and children. 6, 7 The Mahidol live-attenuated dengue 2 virus candidate has also been safely tested in American military volunteers, resulting in good immune responses indistinguishable from those induced in Thai volunteers. 8 The four attenuated strains were transferred to Aventis Pasteur in France for scaling up to industrial manufacture. With the lots produced in France, a first clinical trial was performed in the United States using monovalent vaccines and a tetravalent vaccine given in one dose (4 log 10 of the 50% cell culture infective dose [CCID 50 ] per serotype). 9 In this trial, in flavivirus-naive north American volunteers, monovalent liveattenuated dengue vaccines appeared to induce type-specific antibody responses with 100% seroconversion after immunization with monovalent dengue vaccine types 2, 3, and 4. However, vaccination with the tetravalent dengue vaccine formulation induced antibody responses predominantly directed toward type 3 virus with low or undetectable titers to other types.
To examine whether tetravalent vaccine with lower concentrations of virus would be more immunogenic and whether the observed interference in antibody production against the four serotypes when administered together is related to the ratio between vaccine viruses, we selected the seven formulations of dengue vaccine differing in the total viral dose and relative concentration of each virus ( Table 1 ). The present study was then carried out to determine the safety and immunogenicity of two doses, given six months apart, of the seven formulations of the Aventis Pasteur tetravalent liveattenuated dengue vaccine in Thai adult volunteers. Study population. Six months before vaccination, sera from 6,365 potential subjects were screened for the presence of antibodies to DEN 1-4 and Japanese encephalitis (JE) virus by a hemagglutination-inhibition (HI) test. Those with a negative HI test result were then tested for IgM and IgG to dengue using an enzyme-linked immunosorbent assay (ELISA), and those with a negative ELISA result were further tested for neutralizing antibodies to DEN 1-4 and JE virus using a plaque-reduction neutralizing assay. Persons showing no detectable antibodies to DEN 1-4 and JE virus by all three tests were primarily selected as study subjects.
At a pre-inclusion visit seven days before first vaccination, DEN 1-4 and JE seronegative volunteers were checked for eligibility. Healthy adults (18-40 years) of either sex were eligible. The presence of at least one of the following precluded study enrollment: family history of migraine headaches; existing acute illness; any known or suspected disease of the immune system; immunosuppressive therapy within the preceding year or corticosteroid therapy higher than two weeks within the preceding month; allergy to neomycin, other aminoglycosides, dogs or monkeys; previous yellow fever, Japanese encephalitis or dengue disease or vaccination; presence of abnormal biological values; pregnancy; clinical or serologic evidence of systemic illnesses including active hepatitis B, hepatitis C, infection with human immunodeficiency virus (HIV), syphilis, malaria; and pre-existing antibodies to flavivirus. A blood sample was obtained to evaluate these biological latter parameters (hematology, blood chemistry, coagulation time, hepatitis B, C, and HIV serology, malaria parasite, and pregnancy test) and to confirm the absence of antibodies to flavivirus (ELISA, HI test).
On the day of vaccination, eligibility was confirmed (biological test results were checked) and a further blood sample was obtained for dengue neutralizing antibody titration and baseline biological status. Subjects were then randomly given a first dose of one of seven dengue vaccine formulations or a placebo. A second dose of the same vaccine was given six months later. Volunteers were asked to take measures (using mosquitoes repellant on open areas during day time) to reduce their chances of acquiring natural dengue infections during the study period.
Vaccines. The lyophilized dengue vaccines used in this study were manufactured by Aventis Pasteur (Lyon, France). The parent dengue virus serotypes 1, 2, and 3 were isolated from DHF patients and serotype 4 was isolated from a dengue patient. The parent viruses of types 1, 2, and 4 were attenuated by serial passages in primary dog kidney cell culture, while the parent virus type 3 was attenuated in primary green monkey kidney cell culture and then in fetal rhesus lung cell culture. The parental strains and passages have been described in detail elsewhere. 10 Virus titration was then performed on Vero cells by an indirect immunofluorescence antibody test using serotype specific monoclonal antibodies and expressed as the CCID 50 . Tetravalent dengue vaccines were produced by mixing the monovalent final bulk products of serotypes 1, 2, 3, and 4. The placebo was the solvent used during the vaccine production and contained 50% medium culture and 50% DS21 stabilizer. All vaccines and placebo were identical in appearance. Table 1 summarizes the seven dengue vaccine formulations used and number of subjects in each vaccine group. Subjects were inoculated subcutaneously in the deltoid region with a 0.5 ml dose of vaccine or placebo.
Serology. For screening, the HI assay was performed by the standard Clarke and Casals technique using dengue reference strains.
11 A test dilution Ն 1:10 was considered positive. The ELISA for detection of IgM and IgG antibodies to dengue was performed using the MRL dengue diagnostic kit (MRL Diagnostics, Cypress, CA). Test results were positive for a ratio Ն 1.00 (in comparison to the reference). Neutralizing antibodies were assessed in sera collected before and 28 days after both vaccinations, and additionally 60 days after the first vaccination. A plaque-reduction neutralization assay was performed using the method described by Russell and others. 12 Neutralizing antibodies to DEN 1-4 were evaluated in heatinactivated serum in a 50% plaque reduction assay using LLCMK2 cells. The test was performed using the parental vaccine strains DEN-1 (16007), DEN-2 (16681), DEN-3 (16562), and DEN-4 (1036). The detection cutoff point for the assay was a 1:5 dilution. Test results were positive if titers were Ն 1:10. The results were expressed as the reciprocal of dilution.
The antibody response after each dose was expressed as the observed percentage of subjects with neutralizing antibody titers Ն 1:10 dilution for each dengue serotype, for at least three serotypes, and for all four serotypes. For the first dose, we present the number of subjects with antibody response at day 28 and/or 60. For the purpose of these analyses, subjects with preexisting neutralizing antibody against dengue and/or JE were excluded. In addition, using the IgM:IgG level ratio on days 16 and 28 after the first dose, we evaluated whether subjects with undetectable antibodies could have a possible secondary immune response. Secondary type immune response was considered for an IgM:IgG ratio < 1.8.
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Viremia. Dengue virus isolation and detection were performed on days 2, 8, 10, 12, and 16 after the first injection and days 5, 8, 10, 12 , and 16 after the second. Three techniques were used. The first was inoculation into Toxorhynchites splendens. Head squash preparations were read after 14 days. The second was inoculation into LLCMK2 cells. Fixed infected cells were read on days 7 and 14.
14 Detection of viral 
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antigens was done using polyclonal anti-dengue fluorescein isothiocyanate conjugate. Identification of serotypes was carried out by indirect fluorescence assay using a panel of monoclonal antibodies against the four dengue serotypes. The third method was detection of dengue virus RNA carried out by using serotype-specific primers in a semi-nested polymerase chain reaction as described by Lanciotti and others.
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Safety data collection. After each vaccination the subjects were followed for 30 min to detect any immediate reaction and were given a self-monitoring form to record daily body temperature and local and systemic symptoms for the next 28 days. After the first dose, subjects returned for follow-up visits on days 2, 8, 9, 10, 11, 12, 16, 28, and 60, and after the second dose, subjects returned on days 5, 8, 9, 10, 11, 12, 16, and 28. Safety information was noted by each subject on the self-monitoring form and then collected by the investigator at each visit. Local reactions at the injection site pre-listed in the self-monitoring form included erythema, induration, warmth, pain, and axillary and cervical lymph node enlargement. Prelisted systemic symptoms were those classically observed in dengue disease; 1 i.e., fever, chills, malaise, anorexia, headache, macular or papular rash, blanching, pruritus, petechiae, nausea, vomiting, abdominal pain, myalgia, arthralgia, photophobia, conjunctivitis, and eye pain. The local and systemic adverse reactions were classified by severity (mild, moderate, or severe), time to onset, duration, and relation to the vaccine. Systemic adverse events were classified as mild (aware of symptoms but easily tolerated), moderate (discomforting enough to interfere with normal daily activity), or severe (disabling and requiring bed rest). Oral temperature was recorded twice a day for 28 days after immunization. Severity of fever was classified as mild (Ն 37.5°C but < 38.5°C), moderate (Ն 38.5°but <40°C), or severe (Ն 39°C and sustained over a 24-hr period) (three temperature measurements at least 6 hr apart), or a daily oral temperature Ն 39°C on three successive days or Ն 40°C. For rash, an intensity scale based on body surface area was used:slight (1-20%), minor (21-50%), moderate (51-80%), and severe (81-100%), For the local reactions (erythema and induration), severity was classified according to the reaction diameter as mild (< 2.5 cm), moderate (2.5-5 cm), and severe (> 5 cm).
Biological parameters (including creatinine, alanine aminotransferase [ALT], aspartate aminotransferase [AST], blood cell count, hemoglobin, and hematocrit) were assessed on days 0, 2 (post-dose 1 only), 5 (post-dose 2 only), 8, 10, 12, 16 , and 28 days after each dose. Subjects with abnormal laboratory values were followed until resolution of the abnormality. The cut-off points for abnormal biological values were platelet counts < 200 × 10 9 /L, total white blood cell (WBC) counts < 4.0 × 10 9 /L, neutrophil counts < 2.0 × 10 9 /L, and AST or ALT levels greater than two-fold above the subject's baseline (the average of the two values obtained in the seven days preceding vaccination and on the day of vaccination). Severely abnormal laboratory test results were defined as platelet counts < 90 × 10 9 /L, total WBC counts < 2.0 × 10 9 /L, neutrophil counts < 1.0 × 10 9 /L, and AST or ALT levels >10-fold above the volunteer's baseline. These criteria were similar to those used in the previous dengue vaccine trial. 9 Statistical analysis. Statistic analyses were primarily descriptive. Body mass index at inclusion was calculated in each group. Geometric mean titers (GMTs) of neutralizing antibody levels (after decimal logarithmic transformation) were calculated for each serotype in each group at each time point. A systemic reaction symptom index (SI) was calculated for each subject based on the duration multiplied by the severity score of each systemic reaction (fever, chills, malaise, headache, myalgia, arthralgia, rash, pruritis, eye pain, photophobia, conjunctivitis). For each subject the maximum values between fever versus chills, myalgia versus arthralgia, rash versus pruritus, and eye pain versus photophobia versus conjunctivitis were retained and summed together with the values for malaise and headache. The mean ± SD was calculated for each group. Safety was analyzed on the subjects effectively vaccinated and with at least one follow-up visit for each dose. Safety data of subjects who had primary response and secondary response after the first dose were also compared. Immunogenicity analysis was performed on per protocol subjects (flavivirus seronegative on day 0). All data were analyzed with SAS software version 6.06 (SAS, Inc., Cary, NC).
RESULTS

Subjects.
Only 71 young adults of the 6,365 Thai adult volunteers passed the screening for absence of antibodies to dengue and JE, of whom 12 were found ineligible at the preinclusion visit. The 59 eligible volunteers (54 men and 5 women) were enrolled and randomized to one of the eight groups. We had planned to study 66 subjects, including 12 subjects into each of the two groups receiving the formulations used in previous U.S. and Thai trials, as well as the placebo group, and to include six subjects into each of the five remaining exploratory vaccine formulation groups. The number of subjects in each group after block randomization is shown in Table 1 . The age, height, weight, body mass index, and female:male ratio were similar between groups. The mean age per group was 21-22 years according to the vaccine group (range ‫ס‬ 19-30). Of the 59 who received dose 1, 57 subjects received the second dose of vaccine (two left the study for reasons not related to side effects) and were followed for 28 days. One placebo group subject and one group 5 subject received each others' second dose and were excluded from the second dose analysis. Seven subjects (including one in the placebo group) were found to be flavivirus seropositive on day 0 and were excluded from the perprotocol analysis of immunogenicity but not from the analysis of safety. An additional eight subjects exhibited a possible secondary response to the first vaccination as shown by their IgM:IgG ratio on day 16 or 28 that was < 1.8. These subjects were nevertheless included in the per-protocol immunogenicity analyses.
Clinical reactions. After the first dose, 47 of the 49 subjects who received a dengue vaccine presented systemic reactions. The most frequent systemic reactions in subjects receiving dengue vaccine were headache (43 subjects), rash (42 subjects), eye pain (37 subjects), fever (38 subjects), and myalgia (30 subjects). These reactions occurred mostly between days 7 and 11 and generally lasted three days or less. The placebo group differed sharply in the number of subjects experiencing reactions (5 of the 10 subjects presented a systemic reaction), and in the type of reactions (no fever reaction was reported in placebo group after the first dose). No allergic reactions were noted. The number of subjects with severe reactions is shown in Table 2 .
Five subjects (three in group 1 and two in group 4) were hospitalized for dengue-like fever related to vaccination. These subjects presented clinical symptoms meeting our severity criteria: fever, headache, myalgia, eye pain, malaise for 2-6 days. Two of them (in group 1 and 4) had severe fever. All spontaneously recovered without sequelae. After the second dose, systemic reactions were markedly fewer (24 of 47 subjects) and were mild to moderate. They occurred mainly between days 1 and 7 and lasted for two days or less. There was no rash and no severe systemic adverse reaction after the second dose.
After the first dose, the placebo group presented the lowest Si, followed by the two groups vaccinated with 1 log of dengue virus type 3 (groups 6 and 8). The highest SI scores were in the two groups (1 and 4) in which hospitalization for denguelike fever occurred, and additionally in group 7. After the second dose, the SI was much lower in all groups (Table 2) .
After the first dose, with the exception of two episodes of pain, no severe local reactions were noted. The occurrence of local reactions after the second dose was similar, with one case of severe pain. With the exception of group 8 in which no subject experienced erythema, induration, or pain after either dose, the local reaction profile was similar in all groups, including the placebo group. Local reactions occurred within one day of injection, except adenopathies which occurred 9-10 days later and lasted less than one day.
Fourteen of the 49 dengue vaccine recipients had either pre-existing antibodies against dengue and/or JE on day 0, or exhibited a possible secondary response to the first dose of vaccine (no preexisting antibodies on day 0, but IgM:IgG ratio <1.8). The reactogenicity profile observed in these 14 subjects was compared with that observed in the remaining 35 dengue vaccine recipients. No statistical difference was found between the two subproportions in terms of the proportion of subjects with at least one moderate or severe local or systemic reaction after the first dose (8 [57%] of 14 versus 27 [77%] of 35, respectively).
Biological reactions. Figure 1 shows the proportion of subjects in each group with abnormal blood cell counts and elevated levels of liver enzymes after the first and second vaccinations. After the first dose 33 of the 49 dengue vaccine recipients showed decreased platelet counts and 32 of 49 showed decreased white blood cell counts. The affected white blood cells were neutrophils and lymphocytes. All five subjects hospitalized for dengue-like fever presented neutrophil and platelet count decreases corresponding to the definition of severe (Table 2) . Ten subjects had an increase of AST levels and 17 subjects had an increase of ALT levels, one of which (group 4) showed a severe elevation in the ALT level: a 10-fold increase of the baseline value to 145 U/L on days 10-16 after vaccination. At this time, the AST level was also high: 112 U/L. One week later, the AST and ALT levels returned to normal. After the second dose, few laboratory abnormalities were observed and none were severe.
Immunogenicity. The first dose of any of the seven dengue vaccines induced a high response in 43 flavivirus seronegative subjects) to DEN-3, as shown by the 100% seroconversion (neutralizing antibodies Ն 1:10 on day 28 and day 60) to DEN-3. The seroconversion rate to the other serotypes (rate with neutralizing antibodies Ն 1:10 on day 28 and/or day 60 after the first dose) was lower: 76.7% (33 of 43 subjects) to DEN-1, 60.4% (26 of 43) to DEN-2, and 39.5% (17 of 43) to DEN-4 ( Figure 2 ). The seroconversion rate for these three serotypes increased to 85% (35 of 41), 78% (32 of 41), and 70.7% (29 of 41), respectively, 28 days after the second dose. Fifty-eight percent of the 43 subjects seroconverted to at least three serotypes and 34.8% to all four serotypes after the first dose, increasing to 75.6% and 70.7%, respectively, after the second dose. The GMT against serotype 3 was higher after the first dose than the GMTs against the other serotypes. In contrast, the second dose had a greater effect on the GMTs against serotypes 1, 2, and 4 than it did on the GMT against serotype 3 (Figure 3) .
Antibody prevalence and GMT per group are shown in /L on day 12 after injection that spontaneously resolved in 24 hr. ‡ Five subjects had neutrophil counts between 0.6 and 0. 8 10 9 /L between days 11 and 13, lasting 24 hr in four subjects, and 48 hr in one. § One subject had an ALT value of 145 U/L (11-fold higher than baseline value) on day 16 after injection that spontaneously resolved by day 28. ¶ Mean SI ± SD calculated as the product "duration × severity score" for the reactions fever, chills, malaise, headache, myalgia, arthralgia, rash, pruritus, eye pain, photophobia, and conjunctivitis. The maximum value between fever vs. chills, myalgia vs. arthralgia, rash vs. pruritus, and eye pain vs. photophobia vs. conjunctivitis were retained and summed with the values for malaise and headache. Figure 4 and Table 3 . After the first dose, all subjects in groups 1, 4, and 5 had neutralizing antibodies (Ն 1:10) against serotype 1 ( Figure 4A and Table 3 ). The seroconversion rate in other groups ranged from 25% to 80%. The second dose increased the seroconversion rate in groups 2, 6, and 8 and the GMT particularly in groups 1 and 8.
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After the first dose, all subjects in group 8 seroconverted to serotype 2 ( Figure 4A and Table 3 ). The seroconversion rate was 83% in group 5, 80% in group 4, and lower in the other groups. The second dose increased the response rate and GMT in all groups except group 5.
After the first dose, all dengue vaccine recipients had neutralizing antibodies against serotype 3 with high GMT. The second dose had a moderate to no effect on GMT.
After the first dose, the antibody response to serotype 4 was low ( Figure 4B and Table 3 ). The highest percentage (67%) was observed in group 5 with a GMT of 32.5, 28 days after the first dose. The second dose increased the seroconversion rate in all groups except in group 5 and increased the GMT, particularly in groups 1, 4, and 8.
The second dose increased the rate of seroconversion against at least three serotypes and the rate of seroconversion against all four serotypes. The percentage of subjects with neutralizing antibodies against all four serotypes after two doses was 100% for group 4, 90% for group 1, 75% for groups 6 and 8, and between 40% and 60% for groups 2, 5, and 7. Analysis of the IgM:IgG ratio showed that eight subjects with no pre-existing antibodies on day 0 had IgM:IgG ratios <1.8, which suggests a possible secondary immune response. The individual neutralizing antibody level of these subjects after the first dose is shown in Table 4 . They presented a high antibody response, especially for serotypes 1, 2, and 3.
Viremia. Virus was detected by at least one of the three methods at least once during the 16 days following the first dose in 47 of the 49 dengue vaccine recipients. Viremia after the first dose was mainly DEN-3 (47 subjects); dengue virus types 1, 2, and 4 were detected in four, 10, and five, respectively, of the 49 subjects. After the second dose, virus was detected in 21 of the 47 dengue vaccine recipients. In contrast to the first dose, no DEN-3 viremia was detected. Dengue serotype 4 was most frequently detected (13 subjects). Dengue 1 and 2 were detected in one and 10 subjects, respectively. Virus was most often detected 8-10 days after each dose (Table 5) . DISCUSSION The infrequency and moderation of significant clinical adverse effects in four of the seven vaccine groups strongly indicates that the vaccine is dengue attenuated. After the first dose, most of the subjects experienced mild or moderate systemic reactions. The types of symptoms, while similar to those of dengue fever, were much milder and shorter. We noted clinical dengue-like illness in five subjects from two study groups; three were in group 1, in which subjects received the dengue vaccine with the highest concentration (10 4 CCID 50 per serotype) of all four viruses. The effects observed were similar to those observed when the same formulation was administered to U.S. volunteers. 9 The other two subjects with clinical dengue-like illness were in group 4. The formulation administered to this group was a 100-fold dilution of that given to group 1, but contained the four viruses in the same ratio (10 2 CCID 50 per serotype) as in the group 1 formulation. Thus, based on the results from these small groups, the ratio between the constituent virus serotypes may well be an important determinant of clinical safety. Previous studies of attenuated dengue vaccines have shown a clear reduction in viremia, but the associated adverse events were found to be too severe, outweighing any benefits for use, even in high endemic areas. 5, [16] [17] [18] For the Aventis Pasteur dengue vaccine, among all Thai vaccine recipients asked to evaluate the vaccine, only two in group 1 (in whom reactions were the most severe) indicated that they would refuse the vaccine and would not recommend its use.
Although most vaccine recipients experienced a short period with one or more biological abnormalities, only five presented abnormalities (decreased platelet and white blood cell counts) rated severe (based on grade 3 of the WHO scale of toxicity for neutrophils and white blood cell counts, and grade 1 of the WHO scale for platelet count). The observed hematologic abnormalities in this study are similar to those reported in the classic dengue disease, but were milder and transient (less than 48 hr). 19 The two formulations with one log of dengue virus serotype 3 (formulation 3212 given to group 6 and formulation 4414 given to group 8) demonstrated the best safety profile, as illustrated by the low symptom indexes in each these two groups. The significance of these lower symptom indexes was statistically confirmed by a principal component analysis (data not shown). 2 (A), serotypes 3 or 4 (B) , and at least three serotypes or all four serotypes (C) on day 28 and/or day 60 after the first dose and 28 days after the second dose of dengue vaccine.
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In natural dengue infection, secondary infection is more often associated with DHF than primary infection. Considering the classic mechanism of antibody dependant enhancement, where secondary dengue infection is a risk factor, one could fear that a two-dose vaccination strategy could lead to increased adverse events or even an induction of hemorrhagic fever after a second vaccination. 20 This was a major challenge in our study in which a two-dose strategy was tested for the first time. Of particular importance therefore was the observation that the first dose did not appear to establish a susceptibility to more severe reaction following the second dose. We even observed an important reduction in the frequency and severity of systemic reactions following the second dose. These observations suggest that the attenuated vaccine strains behave differently to wild strains, although concomitant in- #10  150  330  170  260  #13  540  500  390  140  #22  320  440  600  200  #27  120  1300  890  30  #32  270  94  300  27  #38  72  270  760  74  #42  300  800  900  800  #54  5  5  270  5 fection with the four viral strains is an artificial situation for which we have no epidemiologic references. The long-term vaccine safety, and whether vaccination increases susceptibility to an ensuing natural infection will need to be studied in future trials. Our observations of a lower frequency and severity of systemic reactions after the second dose is an important validation of a two-dose approach and supports further dengue vaccine testing in children. Similarly, previous dengue infection (indicated by existing antibodies to dengue/ JE on day 0 or by an IgM:IgG ratio <1.8 on day 16 or day 28) did not appear establish a susceptibility to severe reactions following the first dose with respect to subjects with no evidence of previous dengue infection. Neutralizing antibodies to DEN-3 were largely induced by the first dose of dengue vaccine. The second dose substantially increased the level of antibodies to DEN-1, DEN-2 and DEN-4, but had little further effect on the antibodies to DEN-3. The two-dose dengue vaccination schedule gave satisfactory rates of seroconversion with significant levels of neutralizing antibodies to all four serotypes. We judged the serologic response after dengue immunization to be significant if neutralizing antibodies were induced against all four serotypes. Although the ideal would be complete seroconversion to all four serotypes, seroconversion to three serotypes is likely to be protective to all four since there has been no report of a fourth infection in an individual even when all four serotypes circulate in the same area. 6 Since the two doses were given six months apart and Thailand is a highly endemic country, the possibility exists for a vaccinated volunteer to be naturally infected with a wild type virus prior to the second immunization. A recent study performed in Thailand (Endy TP, unpublished data) showed that during a six-month epidemic period the overall incidence of dengue infection was 152 of 2,214 (6.9%, 95% confidence interval ‫ס‬ 5.8-8.0%). Considering the upper limit of the confidence interval (i.e., 8% and the number of subjects in our study receiving dengue vaccine [n ‫ס‬ 49]), in theory, four subjects could be infected between the two doses. Two minimizing factors should be nevertheless taken into account in our study. First, all the subjects were instructed to use repellent after the end of the first part of the study (day 60) and until the second dose. Second, the study was carried out between October and May, corresponding to a lower transmission period for dengue virus. 21 Thus, there was low likelihood of naturally infection in our vaccinees, which was also confirmed by the control group in which none developed neutralizing antibody against any serotype between the first and second dose. Consequently, we can expect that natural dengue infection between the two doses had a low impact on immunogenicity results. In addition, the effect of the second dose is apparent when one considers the kinetics of the GMT, as shown in Table 3 and Figure 3 .
Besides humoral immunogenicity, we can speculate that cellular immune responses have been stimulated by this liveattenuated dengue vaccine and may play an important role in protection. 22, 23 A recent study has reported that T cell immunity was an important component of the immune response to a monovalent dengue-2 vaccine. 24 In the previous study, while tetravalent vaccination resulted in incomplete antibody responses, evaluation of T cell responses from tetravalent vaccinees showed dengue vaccine-specific proliferative and cytotoxic T lymphocyte responses to dengue-1, dengue-2, and dengue-3 viruses. 9, 25 Further studies are needed to clarify the role of the cellular immune response to dengue virus vaccine.
There was a clear relationship between neutralizing antibodies and viremia. After the first vaccination, nearly all subjects had viremia for serotype 3 and all had neutralizing antibodies against this type. Viremia for the other serotypes was low. In contrast, after the second dose no subject had serotype-3 viremia but both viremia and neutralizing antibodies against serotype 4 increased. It may be that the neutralizing antibodies to DEN-3 produced after the first dose protect against the replication of this serotype at the second dose, allowing other serotypes to replicate and induce antibodies. Quantitative determination of viremia on tissue culture for serotype 3 after the first dose was recently performed in a subpopulation of vaccinees (data not shown). In our limited sample size, there were no clear correlation between the maximal viremia and the vaccine dose administered after the first dose. However, since there were no daily blood samples for detecting viremia, we could have missed the peak viremia in vaccinees.
Monovalent DEN-2, 3, and 4 have previously been reported to induce type-specific antibody responses and 100% seroconversion after a single dose, but the combination of the viruses into multivalent formulations results in unbalanced immune responses. 9 In our study, the immune response against serotype 4 in terms of detectable neutralizing antibodies was low after the first dose in all vaccine groups. These results suggest quantitative and qualitative interactions between dengue serotypes when given in a single dose. Viremia data appear to confirm this hypothesis. Viral interaction is known to occur with other live-attenuated vaccines such as oral polio vaccine (OPV). Due to interactions between the three serotypes of poliovirus in OPV, a three-dose primary immunization is required to attain an adequate antibody response against the three serotypes. 26 Three doses of polio vaccine with a polio 1:2:3 virus dose ratio of 10:1:3 produced a low prevalence of antibodies to type 3, and doubling the type 3 component led to a higher antibody production and seroconversion rate. 27 The present study was conducted in flavivirus-naive adults, but children are the main target for vaccination because the incidence of DHF/DSS is the highest in this population. In areas of high endemicity, vaccination at a very young age might protect against the rare but severe DHF/DSS cases seen during infancy. Moreover, it could prevent primary dengue infection and reduce transmission. Based on the results presented here, is being conducted in Thai children. Other issues that may need to be studied are the safety and immunogenicity of the vaccine in populations previously immunized against dengue or other flaviviruses (JE/yellow fever).
A two-dose dengue vaccination schedule with four different vaccine formulations showed acceptable safety and immunogenicity, overcoming the interactions and suboptimal immunogenicity observed with a single dose regimen. Varying and reducing the concentrations of the serotypes, particularly that of serotype 3, in the different tetravalent formulations has been shown to improve the safety profile. The wellknown lower susceptibility of children compared to adults for dengue symptoms, 8 and the increasing burden of dengue diseases in children living in endemic countries, incite further clinical trials in children.
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